PRIMARY
- Identify immune determinants of response to chemotherapy and immunotherapy regimens in advanced or metastatic endometrial cancer
SECONDARY
- Identify immune determinants of acquired primary and secondary resistance to chemotherapy and immunotherapy regimens in advanced or metastatic endometrial cancer
Institut Paoli Calmettes
232 Boulevard Sainte Marguerite
13273 Marseille Cedex 09
INCLUSION CRITERIA
- Recurrent, advanced or metastatic endometrial cancer with a stable disease, partial or complete response on routine CT scan after a minimum of 3 cycles of Carboplatin-Taxol and Dostarlimab
- For the pilot study performed on patients treated at IPC : Patients with recurrent advanced or metastatic endometrial cancer who underwent delayed surgery after chemotherapy alone will be included as a control arm
- Delayed surgery if operable or post treatment biopsy of primary tumor/metastatic site if external radiotherapy after a minimum of 3 cycles of Carboplatin-Taxol (pilot study) and Dostarlimab (pilot study and validation study)
- Archival FFPE tumor tissue from pre-treatment diagnostic biopsy and post-treatment surgical specimen/ biopsy of primary tumour or metastatic site
- Optionnal: Archival biopsy at recurrence under maintenance immunotherapy if available
EXCLUSION CRITERIA
- No available pre-treatment or post-treatment tumour tissue
- Patients who refuse the collection and use of their personal data within the context of the study
Traitement de données mené dans l'intérêt public dans le domaine de la santé publique (article 6.1e et 9.2.j du Règlement (UE) n°2016/679)
Institut Paoli Calmettes
Les données seront conservées pendant la durée légale en vigueur ou tant qu'elles présenteront un intérêt scientifique